CANFCan-Fite BioPharmaSigning up patients
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Hepatocellular Carcinoma · Cirrhosis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 471 (planned)
- Started
- Mar 15, 2023
- Main results expected
- Feb 2026
- Fully finished
- Oct 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: From the time of randomization until the date of death from any cause, assessed up to 60 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05201404 · record last updated 2025-04-29 · checked 2026-11-09 15:36 UTC